PERSONALIS INC (PSNL)
Health Care · genomic testing and diagnostic services · NASDAQ
Personalis provides ultra-sensitive cancer genomic testing and MRD monitoring to enable personalized cancer therapy and translational research at scale.
What PERSONALIS INC does
Personalis is a genomics company that provides advanced cancer genomic testing services to clinicians, academic researchers, and pharmaceutical companies. Its core platform delivers ultra-sensitive tumor profiling, minimal residual disease (MRD) monitoring, and neoantigen discovery to support personalized cancer therapies and clinical trials. The company also maintains large-scale sequencing capabilities used for population genomics initiatives, including a contract with the U.S. Department of Veterans Affairs.
Themes: cancer diagnostics, personalized medicine, immunotherapy monitoring, population genomics, minimal residual disease testing
Fundamentals
- Price$16.06 as of 2026-10-08 close
- Market cap$1.7B as of 2026-07-29 (share count; price 2026-10-08)
- 1-year return+85.0% 2025-10-08 close $8.68 → 2026-10-08 close $16.06
- P/En/a negative earnings
- Net margin-116.7% FY2025, SEC XBRL
- ROE-31.1% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)-13.3% as of 2026-09-02
- Revenue CAGR (3y)+2.3% SEC XBRL
- Beta2.05 as of 2026-09-02
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How PSNL compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PERSONALIS INC looks technically
PERSONALIS INC (PSNL) is trading 50.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 72 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 50.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +50.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $15.74 | $15.74 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $10.67 | $10.67 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 16.77. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 72 trading days ago — a "golden cross", a bullish long-term signal | 72 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend) | 24.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30) | 48.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($15.68 to $16.77) — its "stochastic" reading is 35 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 34.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 25 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $18.89 | $18.89 |
|---|---|---|
| From the 52-week high | it is 15.0% below its 52-week high (its highest price of the past year) | -15.0% |
| Above the 52-week low | it is 224.1% above its 52-week low (its lowest price of the past year) | +224.1% |
| Below the 52-week high | it is 15.0% below its highest point of the past year | 15.0% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 34 trading days ago | 34 sessions |
| All-time high | its highest closing price on record is $53.46 (set on 2021-01-20) | $53.46 |
| Given back of the 52-week move | over the past year its closes ranged ($5.04 to $18.38), and it has given back roughly a quarter of its rise from last year’s low — 17% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.71 to $10.14. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 17.4% |
| From the all-time high | it is 70.0% below its all-time high | -70.0% |
| Nearest price level | it is trading 0.6% above a support level at $15.96 — a price it turned at twice since 2026-09-15, most recently on 2026-09-28. Since 2024-10-08 it has 18 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.6% |
| All-time low | its lowest closing price on record is $0.891 (set on 2023-11-10) | $0.891 |
| Above the all-time low | it is 1702.5% above its all-time low | +1,702% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4911 between its high and its low — about 3.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4911 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $15.97 and $16.55 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $15.97 – $16.26 – $16.55 |
| Typical daily range (% of price) | its price moves about 3.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.1% |
| Stretch from the 200-day average | it is trading 11.0 daily ranges above its 200-day average price (50.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 11.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.61× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Open gap | it gapped 7.5% below the previous close 32 sessions ago and has not traded back through the level it left behind at 18.38 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -7.5% |
| Gap filled | a 2.0% gap down opened on 2026-09-10 has been "filled" 20 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 20 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 4.3 percentage points (the stock lost 3.3% while the market gained 1.0%) | -4.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 10.0 percentage points (the stock gained 13.8% while the market gained 3.8%) | +10.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 126.6 percentage points (the stock gained 144.1% while the market gained 17.5%) | +126.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 70.0 percentage points (the stock gained 85.0% while the market gained 15.0%) | +70.0% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 12.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 34% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $11.96 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +34.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-07-20 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $15.28 — a volume-weighted average of daily closes over 58 sessions, not a true tick-by-tick VWAP. | +5.1% |
Price levels it has turned at before
PSNL last closed at $16.06 on 2026-10-08. Since 2024-10-08 it has turned at 18 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $15.96 | Support | 0.6% below the last close | turned there twice · 2026-09-15 to 2026-09-28 |
| $11.47 | Support | 28.6% below the last close | turned there three times · 2025-11-26 to 2026-07-29 |
| $9.81 | Support | 38.9% below the last close | turned there twice · 2025-11-10 to 2026-01-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $16.77.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 5 trading days, since 2026-10-02.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke down to a new 20-day low · in a Bollinger Band volatility squeeze · beating the market · Stretched far above its 200-day average (6+ daily ranges) · Trading inside the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$15.44 range $13.00 – $16.25; median $16.25
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PSNL
- Consensus EPS estimate-$0.2533 next reporting period, as of 2026-10-04
- Estimate change, 30 days$0.00 from -$0.2533, on 2026-08-30, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on a limited number of large customers and clinical trials.","Significant history of operating losses and negative net margins.","Subject to an announced definitive merger agreement with Tempus."]
What changed in the latest 10-Q
AI-assisted comparison of PSNL's 10-Q filed 2026-05-07 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) adds 'First Quarter 2026 Highlights' section covering Q1 2026 performance with total revenue of $15.5 million
- Newer filing adds specific Medicare coverage milestone for lung cancer surveillance (Stage I-III NSCLC) received in first quarter 2026
- Newer filing adds Real-Time Variant Tracker feature launch for NeXT Personal
- Newer filing adds published neoadjuvant treatment monitoring results in Journal of Clinical Oncology from PREDICT-DNA prospective study
- Newer filing adds AACR Annual Meeting presentation highlights including colorectal cancer and lung cancer data with specific clinical outcomes (100% negative predictive value, 100% specificity)
- Newer filing updates total sequenced samples to approximately 585,000 human samples (versus 552,000 in older filing)
- Newer filing updates whole human genomes sequenced to approximately 227,000 (versus 206,000 in older filing)
- Newer filing states Tempus partnership agreement extends through November 25, 2029 with specific bundling capabilities described
- Newer filing adds Yale Cancer Center and Aarhus University and British Columbia Cancer and University Health Network to list of collaborations
- Removed:
- Older filing (2025-11-04) contains 'Third Quarter 2025 Highlights' section which is removed in newer filing
- Older filing references Annual Report for fiscal year ended December 31, 2024 filed February 27, 2025, replaced with reference to fiscal year ended December 31, 2025 filed February 26, 2026
- Older filing references Q3 2025 revenue of $14.5 million and specific details about Natera decline of $4.6 million and population sequencing decline of $4.2 million, removed in newer filing
- Older filing mentions 'Accelerated Clinical Adoption' with 4,388 clinical tests and 364% year-over-year growth, removed in newer filing
- Older filing mentions 'Submitted for Medicare Lung Cancer Coverage' as pending action, replaced in newer filing with actual Medicare coverage approval
- Older filing references specific trial data from AstraZeneca Phase 3 NeoADAURA trial and LAURA trial presented at ESMO, removed in newer filing
- Older filing mentions 'Launched Prospective Breast Cancer Utility Study' (CATE clinical trial with Yale), removed from highlights in newer filing
- Older filing states 'As of September 30, 2025, we have not received Medicare coverage reimbursement for NeXT Personal Dx' in Clinical diagnostic definition, removed in newer filing
- Reworded:
- Newer filing reorganizes opening paragraphs: moves discussion of testing services for physicians before pharmaceutical company uses; older filing listed pharma uses first
- Newer filing changes 'advanced cancer genomic tests and services' to 'advanced cancer genomic testing services' in Overview
- Newer filing specifies 'testing services are routinely used' versus older filing's 'products are routinely used'
- Newer filing states Tempus partnership 'enables Tempus to market' and provides specific test bundling details; older filing states 'entered into an agreement with Tempus AI, Inc. to commercialize' without specific terms
- Newer filing emphasizes 'we are primarily focusing on three indications' versus older filing's 'we are initially focusing on three indications'
- Newer filing expands collaboration list by adding Yale Cancer Center, Aarhus University, British Columbia Cancer, and University Health Network to the narrative flow
- Newer filing describes Q1 2026 revenue decline of 25% ($5.1 million) with specific drivers; older filing described Q3 2025 decline of 44% ($11.2 million) with different drivers
- Newer filing notes clinical test revenue increase of $1.1 million or 365% due to Medicare coverage decisions; older filing's prior quarter emphasized sequential and year-over-year growth percentages differently
- Notes:
- The two filings cover different fiscal periods (Q1 2026 vs Q3 2025), making some comparisons reflect temporal progression rather than document revisions
- The 'Components of Operating Results' section appears truncated in both documents at similar points, limiting complete comparison of revenue category definitions
- Older filing's Clinical diagnostic revenue definition regarding Medicare reimbursement status is removed in newer filing but may appear later in the complete document
Risk Factors
- Added:
- Reference to Annual Report for year ended December 31, 2025 filed February 26, 2026 (newer filing) vs. December 31, 2024 filed February 27, 2025 (older filing)
- Updated financial data: net loss of $81.3 million for year ended December 31, 2025 (newer) vs. $81.0 million for year ended December 31, 2024 (older)
- Updated financial data: net loss of $30.0 million for three months ended March 31, 2026 (newer) vs. $57.5 million for nine months ended September 30, 2025 (older)
- Updated accumulated deficit of $661.0 million as of March 31, 2026 (newer) vs. $607.4 million as of September 30, 2025 (older)
- Removed:
- Reference to 'services or products' removed and replaced with 'services' only in second risk factor heading (newer uses 'testing services' specifically)
- Word 'products' removed from the phrase 'other services and products' in the second paragraph of second risk factor; now reads 'other services'
- Phrase 'for our products' changed to 'for our testing services' in the bullet point about reimbursement coverage
- References to 'our services' changed to 'our testing services' throughout the second risk factor
- Partial text at end of older filing ('Some of our present or potential competitors, including Adela, Inc., Caris Life Sciences, Inc., DELFI Diagnostics, Inc., Exac') does not appear in newer filing
- Reworded:
- Changed 'services or products' to 'services' in risk factor title about sales and commercialization strategy
- Changed 'for our services' to 'for our testing services' (multiple instances throughout second risk factor)
- Changed 'for our products' to 'for our testing services' in reimbursement bullet point
- Changed 'our services and products' to 'other services' in development stage description
- Changed 'our services' to 'our testing services' in discussions of market acceptance and commercialization
- Changed 'using our services' to 'using our testing services' in publication discussion
- Changed 'testing our services or features' to 'testing our services' in competitor discussion section
- Notes:
- Older filing text appears truncated at the end; comparison limited to complete text available
- Financial updates reflect normal quarterly/annual reporting cycle and do not indicate document rewording
- Terminology shift from 'services' and 'services or products' to 'testing services' represents clarification of business focus rather than substantive change to risk description
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 4 sells ($266916) — 4 selling insiders
- Last 90 days · read to 2026-10-040 buys · 5 sells ($2M) — 4 selling insiders
- Last 180 days · read to 2026-10-040 buys · 13 sells ($7M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-18. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PSNL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PSNL as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 17,368,183
- Reported value $232,733,649
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PSNL's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PSNL had 8,266,193 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
PSNL had 7.74% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.55 days to cover at the same settlement.
- Reported short interest (shares) 8,266,193
- Short interest (% of shares outstanding) 7.74%
- Prior settlement (shares) 8,384,040
- Reported change -1.41%
- Days to cover (reported) 3.55
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Natera (NTRA)
- Guardant Health (GH)
- Exact Sciences (EXAS)
- Tempus AI (TEM)
- Foundation Medicine
- Illumina (ILMN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PSNL vs…
Frequently asked questions
What does PERSONALIS INC (PSNL) do?
Personalis is a genomics company that provides advanced cancer genomic testing services to clinicians, academic researchers, and pharmaceutical companies. Its core platform delivers ultra-sensitive tumor profiling, minimal residual disease (MRD) monitoring, and neoantigen discovery to support personalized cancer therapies and clinical trials. The company also maintains large-scale sequencing capabilities used for population genomics initiatives, including a contract with the U.S.
What sector is PERSONALIS INC (PSNL) in?
PERSONALIS INC (PSNL) is classified in the Health Care sector. Its industry is genomic testing and diagnostic services. It trades on NASDAQ.
Who are PERSONALIS INC's (PSNL) competitors?
Notable peers of PERSONALIS INC (PSNL) include Natera, Guardant Health, Exact Sciences, Tempus AI and Foundation Medicine. This peer set is informational only — not financial advice.
Is PERSONALIS INC (PSNL) overbought or oversold right now?
PERSONALIS INC (PSNL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 48, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PSNL come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.